Therapeutic solutions for neurodegeneration
There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.
Alzprotect designs and develops innovative therapeutic solutions for these diseases.
Objective: to halt neurodegeneration and restore certain brain functions
An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.
Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.
News
ALZPROTECT Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)
Lille, France — May 19th 2026 — Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States.
“FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer “We can now expand
Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial announces the selection of AADvac1 and AZP2006 for its first two regimens
London, United Kingdom – April 25, 2025 –
The Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF) and Anne-Marie Wills (Massachusetts General Hospital), has selected two promising drug candidates—Axon Neuroscience’s AADvac1 and Alzprotect’s AZP2006—for inclusion in the platform trial as the first two compounds to be evaluated. The trial aims to a